Every 10-Q that LIFELOC TECHNOLOGIES INC (LCTC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LCTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LCTC filings page.
Lifeloc Technologies, Inc. reported higher sales but continued losses for the quarter and six months ended June 30, 2026, while advancing its SpinDetect™ drug-detection platform and increasing leverage. Quarterly revenues were $2.44 million, up 10% from 2025, driven mainly by stronger product sales despite lower royalties and discontinued rental income. Gross profit rose to $1.09 million, with gross margin improving to 45% from 42% on favorable product mix. Operating expenses declined across research and development, sales and marketing, and general and administrative costs, leading to a narrower quarterly net loss of $134,330 versus a loss of $393,639 a year earlier.
For the first half of 2026, revenues were $4.74 million, up 5%, and gross profit increased 13% to $2.08 million, with margins improving to 44%. The six‑month net loss shrank to $287,043 from $686,325 as spending was trimmed while maintaining substantial R&D on SpinDetect™, which is targeted for a limited commercial launch in early 2027. Cash and cash equivalents were $908,208, current liabilities $1.10 million, and total debt included a $1.09 million bank term loan, $797,855 in subordinated debentures, and a new $500,000 related‑party term loan at 10.5% interest secured by substantially all assets. Management believes existing resources under its current plan are sufficient for the next 12 months but acknowledges ongoing operating losses and the potential need for additional capital if sales growth or SpinDetect™ commercialization fall short.
Lifeloc Technologies reported first-quarter 2026 revenue of $2,293,812, up about 1% year over year, driven by slightly higher product sales. Gross profit rose to $987,074, with product gross margin improving to 43% from 40% as cost of sales declined.
The company still posted a net loss of $152,713, but this was narrower than the $292,686 loss a year earlier, with lower research, development, and sales and marketing expenses helping offset higher interest costs. Cash and cash equivalents were $569,330 at March 31, 2026, versus current liabilities of $1,064,101, leaving a modest liquidity cushion.
Lifeloc continues to depend on its core breathalyzer business while investing heavily in its SpinDetect™ drug-detection platform, which it aims to launch commercially in 2026. After quarter-end it added a $500,000 secured loan from its CFO and Board Chairman at 10.5% interest to support development, increasing reliance on related-party financing and leverage.
Lifeloc Technologies, Inc. reported Q3 2025 results. Total revenues were $2,257,448, with product sales of $2,241,331 (up 8% year over year). Gross profit was $906,693 (down 1%), reflecting higher costs. The quarter recorded a net loss of $263,439, or $0.10 per share.
For the nine months ended September 30, 2025, revenues were $6,753,858 and net loss was $949,764. Cash and cash equivalents were $685,097 as of September 30, 2025. Current liabilities were $907,861, and the company cited net liquid assets of $641,692. Outstanding debt was approximately $1.8M, including a term loan at 2.95% and subordinated debentures at 8.25%.
The company continues investing in SpinDetect™ development. Subsequent to quarter-end, it entered a merger agreement with Electronic Systems Technology, Inc.; an S‑4/A was filed on October 15, 2025, with closing subject to shareholder and regulatory approvals. Common shares outstanding were 2,752,616 as of November 10, 2025.